Cadrenal Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cadrenal Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2022 to Q3 2024.
  • Cadrenal Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$2.41M, a 132% decline year-over-year.
  • Cadrenal Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$7.61M, a 37.8% increase year-over-year.
  • Cadrenal Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$8.36M, a 24.5% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$7.61M -$2.41M -$1.37M -132% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$6.24M -$2.39M -$1.39M -139% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$4.85M -$1.66M +$3.51M +67.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$8.36M -$1.14M +$3.87M +77.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 -$12.2M -$1.04M -$10.3K -1.01% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$12.2M -$1M -$501K -99.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$11.7M -$5.17M -$5M -2829% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$6.71M -$5.01M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$1.03M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$502K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$177K Jan 25, 2022 Mar 31, 2022 10-Q 2023-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.